Gelatin Nano-coating for Inhibiting Surface Crystallization of Amorphous Drugs

Teerakapibal, Rattavut; Gui, Yue; Yu, Lian

doi:10.1007/s11095-017-2315-z

Cited by 18 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 More recently, 20 nm thick gelatin efficiently inhibited surface crystallization with no strict requirement of opposite charges between the drug and the stabilizing agent. 16 While these studies highlight the potential of diverse coatings to inhibit surface crystallization, surface coating studies involving polymers used as pharmaceutical excipients are limited. 5,6,13,16,17 The majority of these surface coating studies have focused on the improvement of storage stability of amorphous systems.…”

Section: Introductionmentioning

confidence: 99%

Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?

et al. 2020

View full text Add to dashboard Cite

The distinction between surface and bulk crystallization of amorphous pharmaceuticals, as well as the importance of surface crystallization for pharmaceutical performance, is becoming increasingly evident. An emerging strategy in stabilizing the amorphous drug form is to utilize thin coatings at the surface. While the physical stability of systems coated with pharmaceutical polymers has recently been studied, the effect on dissolution performance as a function of storage time, as a further necessary step toward the success of these formulations, has not been previously studied. Furthermore, the effect of coating thickness has not been elucidated. This study investigated the effect of these polymer-coating parameters on the interplay between amorphous surface crystallization and drug dissolution for the first time. The study utilized simple tablet-like coated dosage forms, comprising a continuous amorphous drug core and thin polymer coating (hundreds of nanometers to a micrometer thick). Monitoring included analysis of both the solid-state of the model drug (with SEM, XRD, and ATR FTIR spectroscopy) and dissolution performance (and associated morphology and solid-state changes) after different storage times. Stabilization of the amorphous form (dependent on the coating thickness) and maintenance of early-stage intrinsic dissolution rates characteristic for the unaged amorphous drug were achieved. However, dissolution in the latter stages was likely inhibited by the presence of a polymer at the surface. Overall, this study introduced a versatile coated system for studying the dissolution of thin-coated amorphous dosage forms suitable for different drugs and coating agents. It demonstrated the importance of multiple factors that need to be taken into consideration when aiming to achieve both physical stability and improved release during the shelf life of amorphous formulations.

show abstract

Section: Introductionmentioning

confidence: 99%

Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Despite the positive results of the above-mentioned techniques in preventing the crystallization of amorphous surfaces, the used materials were still lacking pharmaceutical relevance. To overcome this limitation, further studies utilized biopolymers which were deposited on amorphous surfaces by dip-coating from aqueous solutions based on electrostatic interactions, such as alginate on clofazimine [15], dextran sulfate on loratadine [16], gelatin on indomethacin and nifedipine [17], and chitosan on indomethacin [18]. The coating of amorphous materials with biopolymers not only resulted in improved physical stability but also was able to improve its powder flowability and dissolution performance [18].…”

Section: Introductionmentioning

confidence: 99%

Hot Melt Coating of Amorphous Carvedilol

et al. 2020

View full text Add to dashboard Cite

The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystallization during storage and lumping upon dissolution, which may be improved by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin containing 10% (w/w) and 20% (w/w) of polysorbate 65 (PS65) in a fluid bed coater. Lipid coated amorphous particles were assessed in terms of their physical stability during storage and their drug release during dynamic in vitro lipolysis. The release of CRV during in vitro lipolysis was shown to be mainly dependent on the PS65 concentration in the coating layer, with a PS65 concentration of 20% (w/w) resulting in an immediate release profile. The physical stability of the amorphous CRV core, however, was negatively affected by the lipid coating, resulting in the recrystallization of CRV at the interface between the crystalline lipid layer and the amorphous drug core. Our study demonstrated the feasibility of lipid spray coating of amorphous CRV as a strategy to modify the drug release from amorphous systems but at the same time highlights the importance of surface-mediated processes for the physical stability of the amorphous form.

show abstract

“…Because PDDA is not a pharmaceutical polymer, Teerakapibal et al tested gelatin as a coating polymer. 6 Unlike PDDA, gelatin is a weak polyelectrolyte and not a homopolymer, having both acidic and basic amino acid segments. They found that a gelatin coating can offer similar protection against crystallization and that a gelatin coating is “forgiving” in that it does not require strict pairing of opposite charges.…”

Section: Introductionmentioning

confidence: 99%

Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin

Li¹,

Yu²,

et al. 2019

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

As a result of its higher molecular mobility, the surface of an amorphous drug can grow crystals much more rapidly than the bulk, causing poor stability and slow dissolution of drug products. We show that a nanocoating of chitosan (a pharmaceutically acceptable polymer) can be deposited on the surface of amorphous indomethacin by electrostatic deposition, leading to significant improvement of physical stability, wetting by aqueous media, dissolution rate, powder flow, and tabletability. The coating condition was chosen so that the positively charged polymer deposits on the negatively charged drug. Chitosan coating is superior to gelatin coating with respect to stability against crystallization and agglomeration of coated particles.

show abstract

Gelatin Nano-coating for Inhibiting Surface Crystallization of Amorphous Drugs

Cited by 18 publications

References 19 publications

Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?

Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?

Hot Melt Coating of Amorphous Carvedilol

Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin

Contact Info

Product

Resources

About